NDAORALTABLET
Approved
Sep 2005
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
5
Mechanism of Action
Estrogen Receptor Agonists
Pharmacologic Class:
Estrogen
Indications (5)
moderate to severe vasomotor symptoms due to menopause in a woman with a uterusmoderate to severe vasomotor symptoms associated due to menopause in a woman with a uterusmoderate to severe symptoms of vulvarvaginal atrophy due to menopause in a woman with a uterusa woman with a uterus for the treatment of: Moderate to severe vasomotor symptoms due to menopause
Clinical Trials (5)
A Prospective Multicenter Study on Patients'Satisfaction With Angeliq® Micro in Real Clinical Practice Conducted in Russia
Started May 2017
1,570 enrolled
Menopause
Angeliq Regulatory Post Marketing Surveillance
Started Jun 2007
4,078 enrolled
Postmenopausal PeriodOsteoporosis, Postmenopausal
Effects of Angeliq and Prempro on Blood Pressure and Sodium Sensitivity in Postmenopausal Women With Prehypertension
Started Jan 2007
92 enrolled
PostmenopauseHypertensionPre-Hypertension
Efficacy and Tolerability of Angeliq in Thai Women
Started Sep 2005
55 enrolled
Postmenopause
Effect of Angeliq on Blood Pressure (BP) in Postmenopausal Hypertensive Women
Started Apr 2004
750 enrolled
HypertensionPostmenopause
Loss of Exclusivity
LOE Date
Oct 22, 2031
68 months away
Patent Expiry
Oct 22, 2031
Patent Records (1)
| Patent # | Expiry | Type | Use Code |
|---|---|---|---|
| 8906890 | Oct 22, 2031 | Product | — |